Why the study?
Do collagen cross-link breakers improve cardiovascular stiffness associated with aging, diabetes, and hypertension?
Do collagen cross-link breakers improve cardiovascular stiffness associated with aging, diabetes, and hypertension?
Collagen cross-link breakers represent a potential therapeutic strategy to reduce arterial and myocardial stiffness caused by advanced glycosylation end-products in aging, diabetes, and hypertension.
Answers are grounded in this paper and cite their sources.
Potential option for stiffness in aging, diabetes, and hypertension; leaves open confirmation in randomized trials.
Aging, diabetes, and hypertension are conditions in which arterial and myocardial stiffness is increased. Increased arterial stiffness is manifested by an increased systolic arterial pressure, pulse pressure and pulse wave velocity, whereas increased myocardial stiffness is manifested by impaired left ventricular diastolic filling. Moreover, increased arterial stiffness increases cardiac workload, further aggravating already existing adverse changes in left ventricular structure and function. Indeed, studies in human beings have clearly shown that increased cardiovascular stiffness is a reliable predictor of cardiovascular morbidity and mortality. Increased cardiovascular stiffness is usually attributed to the development of fibrosis (i.e., accumulation of collagen). It has also been recognized that the increased cardiac and vascular stiffness may be due to increased collagen cross-linking due to the formation of advanced glycosylation end-products (AGEs). In agreement with this notion is the finding that an inhibitor of AGEs formation improves vascular stiffness in diabetic rats. More recently, cross-link breakers have been developed, and the beneficial effects of one such agent (ALT-711) have been shown in experimental and clinical settings. This report briefly summarizes age related changes in cardiovascular structure and function and describes results of experimental and clinical studies involving collagen cross-link breakers.
No takes yet. Share an insight, caveat, or question.
Sušić et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: